<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043394</url>
  </required_header>
  <id_info>
    <org_study_id>C015</org_study_id>
    <secondary_id>A8501021, CO15</secondary_id>
    <nct_id>NCT00043394</nct_id>
  </id_info>
  <brief_title>CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients
      with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: To evaluate the safety and tolerability of several dose levels of CPG 7909 (up to a maximum of 0.16 mg/kg) and to determine the maximum tolerated dose (MTD)* of CPG 7909 in combination with Herceptin®</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: To evaluate tumor response and safety of CPG 7909 (at the MTD as determined in Phase I) in combination with Herceptin® in patients with metastatic breast cancer.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I To evaluate tumor response, duration of response, time to disease progression, ECOG performance status, and survival time.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II To evaluate duration of response, time to disease progression, ECOG performance status, and survival time.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Carcinoma, Breast</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.04 mg/kg CpG 7909</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.08 mg/kg CpG 7909</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12 mg/kg CpG 7909 Injection once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.16 mg/kg CpG 7909</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.04 mg/kg CpG 7909</intervention_name>
    <description>0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>PF-03512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.08 mg/kg CpG 7909</intervention_name>
    <description>0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>PF-03512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12 mg/kg CpG 7909</intervention_name>
    <description>0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>PF-03512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.16 mg/kg CpG 7909</intervention_name>
    <description>0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>PF-03512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer with metastases

          -  Tumor that has overexpression of HER2 as documented by being either FISH-positive or
             HER2/neu 3+ confirmed by immunohistochemistry

          -  Patients may have had up to three prior chemotherapy regimens for metastatic disease,
             which may have been given in combination with Herceptin® and which may have been
             discontinued due to toxicities. In addition, patients may have had adjuvant
             chemotherapy.

          -  Phase II only: Must have measurable disease by RECIST criteria (defined in section 8)
             with at least one lesion that can be accurately measured in at least one dimension
             (longest diameter to be recorded) as &gt; 20 mm with conventional techniques, or as &gt; 10
             mm with spiral CT scan

        Exclusion Criteria:

          -  Any prior therapy with anthracycline + Herceptin® concurrently

          -  Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure,
             myocardial infarction within the past 6 months, unstable angina; coronary angioplasty
             within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or
             left ventricular ejection fraction &lt; 50%

          -  Pre-existing autoimmune or antibody-mediated diseases including but not limited to:
             systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's
             syndrome, autoimmune thrombocytopenia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berkely</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126-2641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C015&amp;StudyName=CPG%207909%20Plus%20Herceptin%AE%20In%20Patients%20With%20Metastatic%20Breast%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2002</study_first_submitted>
  <study_first_submitted_qc>August 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2002</study_first_posted>
  <last_update_submitted>March 11, 2009</last_update_submitted>
  <last_update_submitted_qc>March 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>CpG 7909 subcutaneous injection combination with Herceptin® metastatic breast cancer.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

